



Contact: Thomas J Smith
Location: Pasadena, CA
Email: tsmith@auritecpharma.com
Tel: 626-372-0386
Website: www.auritecpharma.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Overview

Industry Sector: Drug Delivery

Company Overview: Auritec has two platform drug delivery technologies with broad applicability to current and pipeline drugs.

Second company founded by TJS: first company pSivida (NASDAQ:PSDV)

Bootstrapped with PSDV founder's stock and NIH grants.

Target Market(s): Big Pharma.

Key Value Drivers

Plexis™ is an injectable platform for delivery of small molecules and peptides for days to weeks.

Indication	Funding
Schizophrenia	R43 MH068925
Arthritis	R43AR053025
Diabetic Retinopathy	R43EY017227
Otoprotection	R43DC008477
Graft Rejection	R43/44AI069674
Parkinson's Disease	R43/44NS049918
HIV MTCT	R43/44AI50146

Aeon® is an implantable platform for delivery of small molecules

Indication	Funding
HIV Microbicides	R21/33AI079791, R21AI076136, GPO-A-00-05-00041
Herpes Simplex	R43AI081552

Competitive Advantage: broad applicability, better kinetics

Plan & Strategy: license

Management

Thomas J. Smith MD, CEO
Amanda Malone PhD, VP Research
Gary Ransom, VP Development

Collaborators include:

CDC
Harvard Medical School
Cal Tech
USC
UC Irvine
U Mass
NC State
University of Kentucky
Albany Medical Center
CONRAD
Cochlear Corp.

Product Development

Projects with Animal Data	Human Phase I/II
Otoprotection	Q1 2011
Parkinson's Disease	Q3 2010
HIV MTCT	Q2 2010
HIV Microbicide	Q3 2010
Herpes Simplex	Q4 2010
Arthritis	Q3 2010